drugset / Trial / NCT06701357
CR-CHOP+X in Previously Untreated DEL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, open-label phase II clinical trial that evaluates the efficacy and safety of CR-CHOP regimen combined with different targeted drugs based on different molecular subtypes in newly diagnosed DEL patients.
Timeline
- Start
- 2024-12-10
- Primary completion
- 2026-12-01
- Completion
- 2028-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg/m2 | — |
| Subject | Orelabrutinib | Small molecule | 150 mg | — |
| Background | Cyclophosphamide | Other / unclassified | 750 mg/m2 | — |
| Background | Doxorubicin | Other / unclassified | 50 mg/m2 | — |
| Background | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |
| Background | Tucidinostat | Small molecule | 20 mg | — |
| Background | Vincristine | Small molecule | 1.4 mg/m2 | — |